US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.57

-0.1300-7.65%

Post-market: 1.570.00000.00%16:00 EST

Volume:430.91K

Turnover:698.25K

Market Cap:29.94M

PE:-3.38

High:1.73

Open:1.69

Low:1.56

Close:1.70

52wk High:2.45

52wk Low:0.7300

Shares:19.07M

Float Shares:14.81M

Volume Ratio:0.84

T/O Rate:2.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4640

EPS(LYR):-0.5085

ROE:-556.87%

ROA:-253.31%

PB:52.54

PE(LYR):-3.09

Loading ...

Overview Company News Filings

MIRA Pharmaceuticals Reports Positive Phase 1 Study Results

Mira announces the token name as MIRA

BRIEF-Mira Pharmaceuticals Reports Positive PTSD Data For Ketamir-2 - SEC Filing

MIRA Pharmaceuticals Reports Positive Ketamir-2 Study Results

Mira Pharmaceuticals - Ketamir-2 in Phase 1 Trial for Neuropathic Pain, Where It Has Demonstrated Favorable Safety Profile to Date

THOMSON REUTERS

Mira Pharmaceuticals Inc - Reports Positive Ptsd Data for Ketamir-2 - SEC Filing

THOMSON REUTERS

Mira Pharmaceuticals Announces Promising Results from Ketamir-2 Study for PTSD Treatment

MIRA Pharmaceuticals Approves 2022 Omnibus Incentive Plan

Mira Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a Clinical Trial with FDA Approval for Neuropathic Pain Study, Following Successful Phase 1 Completion

Mira Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Mira Pharmaceuticals Q2 EPS $(0.09) Beats $(0.13) Estimate

MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models

Mira Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview

Mira Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting

Mira Pharmaceuticals Announces Promising Preclinical Results for Topical Ketamir-2, Comparable to Morphine in Pain Relief Study

BRIEF-Mira Pharmaceuticals Inc - FDA Clears Mira's Ind For Ketamir-2 - SEC Filing

Mira Pharmaceuticals Inc. Receives FDA Clearance for Ketamir-2 IND, Advancing U.S. Clinical Trials for Neuropathic Pain

Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction

Mira Pharmaceuticals Inc. Sells 1,550,741 Shares in Block Sale to Institutional Investor for $2 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MIRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.57,"timestamp":1762289999999,"preClose":1.7,"halted":0,"volume":430910,"hourTrading":{"tag":"盘后","latestPrice":1.57,"preClose":1.57,"latestTime":"16:00 EST","volume":199,"amount":312.43,"timestamp":1762290002077},"delay":0,"floatShares":14806099,"shares":19069300,"eps":-0.464032,"marketStatus":"Post-Mkt","change":-0.13,"latestTime":"11-04 16:00:42 EST","open":1.69,"high":1.725,"low":1.56,"amount":698247.512002,"amplitude":0.097059,"askPrice":1.6,"askSize":194,"bidPrice":1.51,"bidSize":6450,"shortable":3,"etf":0,"ttmEps":-0.464032,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1762304400000},"marketStatusCode":4,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":1.6532,"preClose":1.7,"latestTime":"09:25 EST","volume":35518,"amount":58528.954313199996,"timestamp":1762266356625},"postHourTrading":{"tag":"盘后","latestPrice":1.57,"preClose":1.57,"latestTime":"16:00 EST","volume":199,"amount":312.43,"timestamp":1762290002077},"volumeRatio":0.837299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":14806099,"roa":"-253.31%","roe":"-556.87%","lyrEps":-0.508455,"volumeRatio":0.837299,"shares":19069300,"dividePrice":0,"high":1.725,"amplitude":0.097059,"preClose":1.7,"low":1.56,"week52Low":0.73,"pbRate":"52.54","week52High":2.45,"institutionHeld":0,"latestPrice":1.57,"committee":0.941601,"eps":-0.464032,"divideRate":0,"volume":430910,"delay":0,"ttmEps":-0.464032,"open":1.69,"prevYearClose":1.14,"prevWeekClose":1.67,"prevMonthClose":1.67,"prevQuarterClose":1.36,"fiveDayClose":1.7,"twentyDayClose":1.31,"sixtyDayClose":1.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"MIRA","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1755752400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-11-03","current":-3.383387,"percent":0.137291,"low":-15.501022,"twenty":-3.600564,"median":-2.203275,"eighty":-1.502808,"high":-0.648567,"avg":-3.29713,"sd":3.133977,"marketCap":34769926},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067},{"date":"2025-05-16","current":-3.015077,"twenty":-3.060231,"median":-1.929591,"eighty":-1.33782,"marketCap":23875388},{"date":"2025-05-23","current":-2.611651,"twenty":-3.060231,"median":-1.942197,"eighty":-1.340821,"marketCap":20680794},{"date":"2025-05-30","current":-2.845213,"twenty":-3.032803,"median":-1.954767,"eighty":-1.341164,"marketCap":22530296},{"date":"2025-06-06","current":-2.927246,"twenty":-3.016719,"median":-1.959543,"eighty":-1.343476,"marketCap":23179883},{"date":"2025-06-13","current":-2.649478,"twenty":-3.012039,"median":-1.970481,"eighty":-1.352726,"marketCap":20980332},{"date":"2025-06-20","current":-2.628111,"twenty":-2.999889,"median":-1.99311,"eighty":-1.352726,"marketCap":20811136},{"date":"2025-06-27","current":-2.585377,"twenty":-2.991346,"median":-2.003743,"eighty":-1.36142,"marketCap":20472743},{"date":"2025-07-03","current":-2.564011,"twenty":-2.980626,"median":-2.014046,"eighty":-1.36845,"marketCap":20303547},{"date":"2025-07-11","current":-2.564011,"twenty":-2.973678,"median":-2.023876,"eighty":-1.374721,"marketCap":20303547},{"date":"2025-07-18","current":-4.711669,"twenty":-3.002927,"median":-2.037346,"eighty":-1.385099,"marketCap":37310135},{"date":"2025-07-25","current":-4.058566,"twenty":-3.076478,"median":-2.047338,"eighty":-1.397154,"marketCap":32138433},{"date":"2025-08-01","current":-3.84864,"twenty":-3.389372,"median":-2.057134,"eighty":-1.420873,"marketCap":30476100},{"date":"2025-08-08","current":-3.195538,"twenty":-3.551253,"median":-2.064723,"eighty":-1.428551,"marketCap":25304398},{"date":"2025-08-15","current":-3.428789,"twenty":-3.546261,"median":-2.076725,"eighty":-1.436037,"marketCap":27151435},{"date":"2025-08-22","current":-3.438101,"twenty":-3.551253,"median":-2.088717,"eighty":-1.466225,"marketCap":26697041},{"date":"2025-08-29","current":-3.438101,"twenty":-3.546261,"median":-2.106877,"eighty":-1.473341,"marketCap":26697041},{"date":"2025-09-05","current":-3.388985,"twenty":-3.525507,"median":-2.115909,"eighty":-1.473341,"marketCap":26315654},{"date":"2025-09-12","current":-4.076606,"twenty":-3.546416,"median":-2.135501,"eighty":-1.477279,"marketCap":31655062},{"date":"2025-09-19","current":-3.118849,"twenty":-3.546416,"median":-2.135501,"eighty":-1.484806,"marketCap":24218030},{"date":"2025-09-26","current":-3.192522,"twenty":-3.525507,"median":-2.152685,"eighty":-1.488074,"marketCap":24790109},{"date":"2025-10-03","current":-3.290754,"twenty":-3.49704,"median":-2.155092,"eighty":-1.488074,"marketCap":25552882},{"date":"2025-10-10","current":-3.290754,"twenty":-3.487217,"median":-2.162526,"eighty":-1.49011,"marketCap":25552882},{"date":"2025-10-17","current":-4.420416,"twenty":-3.487217,"median":-2.173611,"eighty":-1.498272,"marketCap":34324767},{"date":"2025-10-24","current":-3.806469,"twenty":-3.546416,"median":-2.185002,"eighty":-1.502808,"marketCap":29557438},{"date":"2025-10-31","current":-4.424118,"twenty":-3.578069,"median":-2.201174,"eighty":-1.502808,"marketCap":34353519},{"date":"2025-11-03","current":-4.477744,"twenty":-3.600564,"median":-2.203275,"eighty":-1.502808,"marketCap":34769926}],"updateTime":1762289369233},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2569781076","title":"MIRA Pharmaceuticals Reports Positive Phase 1 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2569781076","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569781076?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:59","pubTimestamp":1758542351,"startTime":"0","endTime":"0","summary":"The latest update is out from MIRA Pharmaceuticals, Inc. ( ($MIRA) ). On September 22, 2025, MIRA Pharmaceuticals announced favorable topline resul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2569785892","title":"Mira announces the token name as MIRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2569785892","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569785892?lang=en_us&edition=fundamental","pubTime":"2025-09-22 17:58","pubTimestamp":1758535080,"startTime":"0","endTime":"0","summary":"BlockBeats News, September 22, Decentralized AI Infrastructure Mira announced that its token would be named MIRA.Previously reported on August 27, Mira announced the establishment of a foundation, which will serve as the long-term steward of the Mira Network, focusing on decentralized network and protocol governance, and providing tooling support for developers, researchers, and the community.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/313307","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/313307","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2567140153","title":"BRIEF-Mira Pharmaceuticals Reports Positive PTSD Data For Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2567140153","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567140153?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:17","pubTimestamp":1757971041,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Reports Positive PTSD Data For Ketamir-2 - SEC FilingSept 15  - SEC FILING:MIRA PHARMACEUTICALS INC - REPORTS POSITIVE PTSD DATA FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - ANIMALS DOSED WITH KETAMIR-2 ONCE DAILY FOR FIVE DAYS - SEC FILINGMIRA PHARMACEUTICALS - KETAMIR-2 IN PHASE 1 TRIAL FOR NEUROPATHIC PAIN, WHERE IT HAS DEMONSTRATED FAVORABLE SAFETY PROFILE TO DATESource text: [ID:n0001493152-25-013459]Further company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V20IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2567406147","title":"MIRA Pharmaceuticals Reports Positive Ketamir-2 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2567406147","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567406147?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:39","pubTimestamp":1757968743,"startTime":"0","endTime":"0","summary":"An update from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. MIRA Pharmaceuticals announced positive results from a proof-of-concept stu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-ketamir-2-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-ketamir-2-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2567424291","title":"Mira Pharmaceuticals - Ketamir-2 in Phase 1 Trial for Neuropathic Pain, Where It Has Demonstrated Favorable Safety Profile to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2567424291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567424291?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:03","pubTimestamp":1757966623,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V20IL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2567142486","title":"Mira Pharmaceuticals Inc - Reports Positive Ptsd Data for Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2567142486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567142486?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:03","pubTimestamp":1757966623,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V20IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2567438142","title":"Mira Pharmaceuticals Announces Promising Results from Ketamir-2 Study for PTSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2567438142","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567438142?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:03","pubTimestamp":1757966596,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced positive results from a proof-of-concept validation study of its oral drug candidate, Ketamir-2, aimed at treating post-traumatic stress disorder . The study, conducted on rats using the Single Prolonged Stress model, showed that Ketamir-2 restored normalized behavior in stressed animals. Animals were exposed to a predator stressor, which induced PTSD-like symptoms, and were then treated with Ketamir-2. The treatment was associated with a reversal of PTSD-like behaviors to levels observed in non-stressed animals. Ketamir-2 targets the NMDA receptor with low affinity and has demonstrated superior efficacy in preclinical studies compared to ketamine, pregabalin, and gabapentin. It is not considered a controlled substance by the U.S. Drug Enforcement Administration. The company is conducting a larger follow-on PTSD study and a Phase 1 clinical trial for neuropathic pain, where Ketamir-2 has shown a favorable safety profile.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLQHNbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2566912555","title":"MIRA Pharmaceuticals Approves 2022 Omnibus Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2566912555","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566912555?lang=en_us&edition=fundamental","pubTime":"2025-09-12 05:48","pubTimestamp":1757627320,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an announcement. On September 11, 2025, MIRA Pharmaceuticals, Inc. held its Annual Meeting of Sha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-approves-2022-omnibus-incentive-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-approves-2022-omnibus-incentive-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2566914196","title":"Mira Pharmaceuticals Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2566914196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566914196?lang=en_us&edition=fundamental","pubTime":"2025-09-12 05:25","pubTimestamp":1757625959,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on September 11, 2025. During the meeting, several proposals were put forward for approval. Shareholders approved the company's 2022 Omnibus Incentive Plan, which increases the number of shares reserved under the plan and allows for the repricing of options or stock appreciation rights. Additionally, the proposal to approve the acquisition of SKNY Pharmaceuticals, Inc. was also approved, marking a significant milestone for MIRA Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL972wyW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2560196237","title":"Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a Clinical Trial with FDA Approval for Neuropathic Pain Study, Following Successful Phase 1 Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2560196237","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560196237?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:01","pubTimestamp":1755604907,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a Clinical Trial with FDA Approval for Neuropathic Pain Study, Following Successful Phase 1 Completion. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDLHjsBT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2559100999","title":"Mira Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559100999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559100999?lang=en_us&edition=fundamental","pubTime":"2025-08-16 00:14","pubTimestamp":1755274486,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryMira Pharmaceuticals Inc MIRA.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nL8N3U70YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2559962810","title":"Mira Pharmaceuticals Q2 EPS $(0.09) Beats $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559962810","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559962810?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:55","pubTimestamp":1755204924,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 18.18 percent increase over losses of $(0.11) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47141181/mira-pharmaceuticals-q2-eps-0-09-beats-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mira Pharmaceuticals Q2 EPS $(0.09) Beats $(0.13) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2558664215","title":"MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2558664215","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558664215?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:02","pubTimestamp":1755000131,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLC7QCw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2558983726","title":"Mira Pharmaceuticals Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558983726","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558983726?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:13","pubTimestamp":1754943186,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc  expected to post a loss of13cents a share - Earnings Preview Mira Pharmaceuticals Inc MIRA.OQ MIRA.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nL8N3U31EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2558577800","title":"Mira Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2558577800","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558577800?lang=en_us&edition=fundamental","pubTime":"2025-08-09 05:17","pubTimestamp":1754687820,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. is set to hold its annual meeting of stockholders on September 11, 2025. The meeting will be conducted exclusively online via a live audio-only webcast. During this important meeting, stockholder approvals will be sought for certain matters, including the proposed Merger.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL2dfcfg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2555066783","title":"Mira Pharmaceuticals Announces Promising Preclinical Results for Topical Ketamir-2, Comparable to Morphine in Pain Relief Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2555066783","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555066783?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:02","pubTimestamp":1753819362,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Announces Promising Preclinical Results for Topical Ketamir-2, Comparable to Morphine in Pain Relief Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL5RJttj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2555670171","title":"BRIEF-Mira Pharmaceuticals Inc - FDA Clears Mira's Ind For Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2555670171","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555670171?lang=en_us&edition=fundamental","pubTime":"2025-07-29 05:03","pubTimestamp":1753736633,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - FDA Clears Mira's Ind For Ketamir-2 - SEC FilingMira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - FDA CLEARS MIRA'S IND FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - PRECLINICAL DATA SHOWS ANALGESIC EFFECTS AND SAFETY - SEC FILINGMIRA PHARMACEUTICALS INC - KETAMIR-2 ACHIEVES GOOD BIOAVAILABILITY AND PENETRATION - SEC FILINGMIRA PHARMACEUTICALS INC - PLANS PHASE 2A TRIAL IN U.S. Q4 2025 - SEC FILINGSource text: [ID:n0001641172-25-021155]Further company coverage: MIRA.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP23L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2555709569","title":"Mira Pharmaceuticals Inc. Receives FDA Clearance for Ketamir-2 IND, Advancing U.S. Clinical Trials for Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2555709569","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555709569?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:02","pubTimestamp":1753732937,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Inc.  has announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for Ketamir-2, a novel oral NMDA receptor antagonist aimed at treating neuropathic pain. This regulatory approval enables MIRA to initiate U.S.-based clinical trials. Ketamir-2 has demonstrated superior efficacy to existing treatments such as gabapentin and pregabalin in preclinical studies, with a favorable safety profile and no evidence of ketamine-associated neurotoxicity. MIRA is advancing through Phase 1 trials and plans to initiate U.S. Phase 2a trials by the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL2psPh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2550675725","title":"Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction","url":"https://stock-news.laohu8.com/highlight/detail?id=2550675725","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550675725?lang=en_us&edition=fundamental","pubTime":"2025-07-11 04:20","pubTimestamp":1752178808,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL3fq2NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2550575922","title":"Mira Pharmaceuticals Inc. Sells 1,550,741 Shares in Block Sale to Institutional Investor for $2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2550575922","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550575922?lang=en_us&edition=fundamental","pubTime":"2025-07-09 05:26","pubTimestamp":1752009962,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. announced that on July 3, 2025, it sold a total of 1,550,741 shares of its common stock to an institutional investor at an average price of $1.2981 per share. The transaction, conducted through its at-the-market equity offering facility, generated approximately $2.0 million in gross proceeds. The transaction was facilitated by Rodman & Renshaw via the StockBlock platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLc2xNL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":76,"code":"91000000","status":"200"}]}}